Author:
von Minckwitz G.,Blohmer J.-U.,Raab G.,Löhr A.,Gerber B.,Heinrich G.,Eidtmann H.,Kaufmann M.,Hilfrich J.,Jackisch C.,Zuna I.,Costa S.D.
Reference16 articles.
1. Dose-dense doxorubicin and docetaxel with or without tamoxifen a spreoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled;Von Mickwitz;open phase IIb study. J Clin Oncol,2001
2. Dose-dense biweekly (8 weeks) versus sequential (24 weeks) neoadjuvant chemotherapy with doxorubicin–cyclophosphamide and docetaxel in operable breast cancer–2nd Interim Analysis of the GABG GEPAR-DUO Trial;Jackisch;Clin Breast Cancer,2002
3. TAC improves disease-free survival and overall survival over FAC in node positive early breast cancer patients. BCIRG 001: 55 months follow up. 26th San Antonio Breast Cancer Meeting;Martin,2003
4. Extended phase I study of capecitabine in combination with vinorelbine in pretreated patients with metastatic breast cancer;Welt;Breast Cancer Res Treat,2002
5. Vinorelbine and capecitabine (VX) for advanced breast cancer — a phase II study showing good activity and potential for further development;Stuart;Proc Am Soc Clin Oncol,2003
Cited by
162 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献